Skip to content

Stereotaxis STXS Cash & Equivalents

Cash & Equivalents at other companies

Abbott logo
AbbottABT
$6.8B+4.1%
Boston Scientific logo
Boston ScientificBSX
$850M+146%
Medtronic logo
MedtronicMDT
$1.95B-12.1%
Stryker logo
StrykerSYK
$2.88B+24.1%
ITG
Integer HoldingsITGR
$8.12M-74.4%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$488.08M+23.4%

Other financials

Income statement

See full
Revenue$6.3M-15.8%
Gross profit$3.8M-6.6%
Operating income-$6.0M-0.9%
Net income-$5.9M-0.7%
EPS (diluted)-$0.06+14.3%

Balance sheet

See full
Total debt$5.3M-10.0%
Total equity$14.4M+399%
Total assets$54.0M+18.2%

Cash flow

See full
Operating cash flow-$3.4M-93.5%
CapEx$79.0K
Free cash flow-$3.5M

Valuation

See full
Market cap$168.11M-11.6%
Enterprise value$158.77M-15.9%
P/S5.4×-0.6×

Profitability

See full
Gross margin53.9%+0.5pp
Operating margin-71%-14.0pp
Net margin-69.5%-13.7pp
FCF margin-35.5%-2.4pp

Returns & leverage

See full
Return on equity-251.5%-29.9pp
Debt / equity0.4×-1.7×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Stereotaxis’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stereotaxis's cash & equivalents?
Stereotaxis (STXS) reported cash & equivalents of $14.62M in Q1 2026.
How has Stereotaxis's cash & equivalents changed year-over-year?
Stereotaxis's cash & equivalents increased by 36.7% year-over-year, from $10.69M to $14.62M.
What is the long-term trend for Stereotaxis's cash & equivalents?
Over 5 years (2020 to 2025), Stereotaxis's cash & equivalents has grown at a -21.1% compound annual growth rate (CAGR), from $43.94M to $13.42M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.